Peer-reviewed research, clinical case reports, AI validation studies, expert editorials and comprehensive books from the global pathology community.
The flagship journal of Global Pathology Publications, featuring original research, clinical insights, and expert commentary.
Cover story on transformer-based models reshaping histopathology analysis, with perspectives from leading AI researchers.
Case studies of complete digital pathology implementation from laboratories in the Gulf and Europe.
Next-generation sequencing in clinical pathology, liquid biopsy advances, and companion diagnostics.
Interviews with pathology leaders from 12 countries on the future of AI-assisted diagnostics and workforce development.
Head-to-head evaluation of six leading whole slide imaging platforms across resolution, speed, and workflow integration.
Step-by-step framework for selecting, validating, and deploying AI tools in clinical pathology practice.
An exclusive interview with a pioneer in computational pathology on the convergence of AI, genomics, and tissue diagnostics.
Key performance indicators reflecting the reach, rigour, and influence of the Global Pathology Review across the international pathology community.
PubMed / MEDLINE, Scopus, Web of Science (ESCI), DOAJ, Google Scholar, EMBASE, CrossRef. All articles receive a DOI and are permanently archived via CLOCKSS and Portico.
The Global Pathology Review is a gold open access journal. All articles are published under CC BY 4.0 licence, ensuring unrestricted access for researchers, clinicians, and educators worldwide. No article processing charges for authors from low- and middle-income countries.
We adhere to COPE (Committee on Publication Ethics) guidelines, ICMJE recommendations, and EQUATOR Network reporting standards. All submissions undergo plagiarism screening via iThenticate prior to peer review.
Editor-selected articles representing the highest impact and clinical relevance from recent issues of the Global Pathology Review.
This prospective study validates a convolutional neural network for automated detection of invasive breast carcinoma across 12 laboratories in 7 countries. Using a dataset of 14,800 whole slide images, the model achieved a sensitivity of 97.3% and specificity of 94.1%, demonstrating non-inferiority to expert pathologist consensus. Subgroup analysis confirmed consistent performance across diverse tissue preparation protocols and scanner vendors.
Integrating transcriptomic, proteomic, and methylation data from 3,200 lung adenocarcinoma specimens, this study identifies a 15-gene signature that independently predicts recurrence-free survival. The signature was validated in three external cohorts and outperformed existing clinical staging in multivariate analysis. The findings support the incorporation of molecular profiling into routine prognostic assessment for early-stage lung adenocarcinoma.
This non-inferiority validation study compares whole slide imaging against conventional light microscopy for primary diagnosis across 8,500 surgical pathology cases. The overall concordance rate was 98.7%, with discordance primarily confined to cases requiring polarised light. The study provides evidence supporting regulatory approval of WSI for primary diagnostic use and establishes a standardised validation framework adaptable to diverse laboratory settings.
This retrospective case series from 11 institutions across the Middle East, Europe, and Asia characterises the clinicopathological features of primary cutaneous gamma-delta T-cell lymphoma. The study describes distinctive immunophenotypic patterns, including aberrant CD56 expression in a subset of cases, and identifies tumour thickness greater than 4 mm and subcutaneous involvement as independent adverse prognostic factors. Treatment outcomes with various chemotherapy regimens and stem cell transplantation are compared.
Developed through a modified Delphi process involving 62 renal pathologists from 28 countries, these consensus recommendations establish standardised terminology and minimum reporting requirements for medical renal biopsies. The guidelines cover light microscopy, immunofluorescence, and electron microscopy reporting, with specific criteria for adequacy assessment and lesion quantification. An accompanying synoptic reporting template is provided to facilitate implementation across diverse practice settings.
This international ring study evaluates inter-assay and inter-observer concordance for PD-L1 immunohistochemistry scoring across the SP142, SP263, 22C3, and 28-8 assays. Using 6,000 non-small cell lung cancer specimens scored independently by 48 pathologists, the study demonstrates substantial agreement for tumour proportion score but moderate agreement for combined positive score. The findings support the clinical interchangeability of SP263 and 22C3 at the 50% threshold and inform companion diagnostic selection in resource-limited settings.
In this prospective cohort of 1,850 patients with stage II-III colorectal cancer, serial circulating tumour DNA analysis using a personalised tumour-informed assay detected molecular relapse a median of 8.4 months before radiological recurrence. ctDNA positivity at the first post-operative assessment was independently associated with inferior disease-free survival (HR 6.7, 95% CI 4.2-10.8). The study supports the integration of liquid biopsy into post-surgical surveillance protocols and provides a framework for ctDNA-guided adjuvant therapy decisions.
This technical report provides a comprehensive framework for deploying computational pathology at scale across multi-site laboratory networks. Drawing on implementation experience from 16 laboratories, the report addresses storage architecture for whole slide images, network bandwidth requirements, DICOM compatibility, data governance for machine learning training sets, and bidirectional integration with laboratory information systems. Practical guidance is offered on vendor evaluation, validation protocols, and change management strategies that have proven effective in accelerating adoption.
This systematic review and meta-analysis evaluates the diagnostic performance of AI algorithms for distinguishing melanoma from benign melanocytic naevi in histopathological images. Pooling data from 38 studies comprising 127,000 lesions, the analysis demonstrates a summary sensitivity of 93.8% and specificity of 91.2% for AI-only assessment. Hybrid AI-pathologist workflows achieved the highest overall accuracy, reducing both false positives and false negatives compared to either modality alone. Current limitations, including dataset bias and generalisability across skin types, are critically appraised.
Addressing the diagnostic challenge of indeterminate thyroid cytology (Bethesda categories III and IV), this study evaluates the feasibility and diagnostic yield of a targeted next-generation sequencing panel applied to residual material from fine-needle aspirates. Among 840 indeterminate aspirates, adequate DNA for sequencing was obtained in 94.2% of cases. The molecular panel reclassified 67% of indeterminate cases as either benign or suspicious, with a negative predictive value of 97.1% for cases without detectable mutations. The findings support the integration of molecular testing into cytopathology workflows for indeterminate thyroid nodules.
Explore our peer-reviewed research organised by pathology subspecialty. Each category is curated by subject-area editors with deep expertise.
Original research in diagnostic surgical pathology covering tumour classification, grading systems, margin assessment, intraoperative consultation, and immunohistochemical interpretation. Emphasis on reproducibility of diagnostic criteria and emerging ancillary techniques that refine morphological diagnosis.
Research spanning next-generation sequencing, companion diagnostics, liquid biopsy, methylation profiling, and gene expression analysis in clinical pathology. Covers validation of molecular assays, turnaround time optimisation, and the integration of genomic data into multidisciplinary tumour board decision-making.
Whole slide imaging validation, computational pathology algorithms, deep learning for diagnosis and prognosis, regulatory considerations for AI-based diagnostics, and digital workflow implementation. Includes foundation model evaluations, explainability methods, and prospective clinical validation studies of AI decision support tools.
Research in lymphoma classification, leukaemia diagnostics, bone marrow biopsy interpretation, flow cytometry, and haematological malignancy prognostication. Coverage includes minimal residual disease monitoring, emerging entities in the ICC and WHO classification systems, and the application of genomic techniques to refine diagnostic and prognostic categories.
Fine-needle aspiration techniques, liquid-based cytology, telecytology, and the integration of molecular testing with cytological diagnosis. Includes research on standardised reporting systems (Bethesda, Paris, Milan), adequacy assessment, and the role of rapid on-site evaluation in interventional procedures.
Melanocytic lesion assessment, inflammatory dermatoses, cutaneous lymphoma, and Mohs micrographic surgery pathology. Research covers AI applications in melanoma detection, immunohistochemical panels for spindle cell lesions, and molecular classification of ambiguous melanocytic tumours including BAP1-inactivated melanocytomas and deep penetrating naevi.
Central nervous system tumour classification, neurodegenerative disease pathology, muscle and nerve biopsy interpretation, and molecular neuropathology. Includes methylation-based CNS tumour classification, the evolving landscape of IDH-mutant gliomas, and the role of digital pathology in frozen section interpretation for intraoperative neurosurgical consultation.
Biomarker discovery, assay validation, quality assurance, point-of-care testing, and laboratory automation. Research includes liquid biopsy analytics, mass spectrometry applications in clinical diagnostics, harmonisation of reference intervals, and the design and validation of laboratory-developed tests under evolving regulatory frameworks.
The five most-cited articles in the Global Pathology Review, reflecting research that has shaped clinical practice and influenced subsequent investigation across the discipline.
Prof. Ravi Krishnamurthy, Dr. Catherine Dubois, Dr. Hiroshi Yamamoto, Dr. Sarah Jensen et al. · Global Pathology Review 2023; 9(4): 412-438 · DOI: 10.58907/gpp.2023.0412
Established the first internationally endorsed protocol for validating whole slide imaging systems for primary diagnostic use. The guideline has been adopted by regulatory agencies in 14 countries and cited in the European Commission IVDR guidance documents. Provided minimum case number requirements, concordance thresholds, and a phased implementation roadmap.
Dr. Amara Okonkwo, Prof. Wei-Lin Chen, Dr. Lena Hoffmann, Dr. Takeshi Nakamura et al. · Global Pathology Review 2024; 10(2): 201-234 · DOI: 10.58907/gpp.2024.0201
Benchmarked 14 foundation models for histopathology against standardised datasets spanning 23 tissue types and 9 diagnostic tasks. Established performance baselines that have become the reference standard for subsequent computational pathology publications. Identified critical gaps in model performance on rare entities and underrepresented tissue preparations.
Dr. Hiroshi Yamamoto, Prof. Catherine Dubois, Dr. Alejandro Vargas-Pinto, Dr. Aisha Mohammed et al. · Global Pathology Review 2024; 10(1): 78-112 · DOI: 10.58907/gpp.2024.0078
Proposed a unified scoring framework for PD-L1 immunohistochemistry across tumour types and assay platforms. The position paper synthesised data from ring studies involving 120 pathologists across 42 centres and provided algorithm-specific interpretation guidance. Has informed subsequent clinical trial protocol design and regulatory submissions for companion diagnostics.
Dr. Sofia Papadimitriou, Dr. Marco Rossi, Prof. Nadia Benhaddou, Dr. Jonathan Park et al. · Global Pathology Review 2024; 10(3): 312-340 · DOI: 10.58907/gpp.2024.0312
Validated an AI system for Gleason grading against an international panel of 24 uropathologists using 6,200 prostate needle biopsies. The AI achieved pathologist-level performance for ISUP grade group assignment and demonstrated particular value in reducing interobserver variability for borderline Gleason 3+4 versus 4+3 cases. Provided the first head-to-head comparison of AI and sub-specialist consensus in a prospective clinical setting.
Dr. Isabelle Moreau, Dr. Kwame Asante, Prof. Dimitrios Nikolaou, Dr. Mei-Hua Lin et al. · Global Pathology Review 2023; 9(3): 278-315 · DOI: 10.58907/gpp.2023.0278
Systematic review of 142 studies evaluating ctDNA, circulating tumour cells, and exosomal nucleic acids for diagnosis, monitoring, and treatment selection in solid malignancies. Established evidence-based recommendations for analytical validation requirements and clinical reporting standards. Identified colorectal, breast, and non-small cell lung cancer as the tumour types with the strongest evidence supporting clinical implementation of liquid biopsy.
The Editorial Board of the Global Pathology Review comprises internationally recognised experts who guide the scientific direction, peer review standards, and strategic vision of the journal.
Editor-in-Chief
Digital Pathology & Computational Diagnostics
Indian Institute of Medical Sciences, Bangalore
Professor Krishnamurthy is a pioneer in the application of computational methods to histopathological diagnosis. His laboratory developed one of the first clinically validated AI tools for breast cancer grading. He has published over 220 peer-reviewed articles and serves on the WHO Digital Health Advisory Committee.
Deputy Editor
Molecular Pathology & Companion Diagnostics
Université Claude Bernard Lyon 1, France
Professor Dubois leads the European Molecular Pathology Consortium and has been instrumental in the development of pan-European guidelines for companion diagnostic testing. She has authored definitive reviews on PD-L1 harmonisation and NGS validation that are widely cited in the field.
Associate Editor, Immunopathology
Immunohistochemistry & Biomarker Standardisation
Nagoya University Hospital, Japan
Dr. Yamamoto is internationally recognised for his work on immunohistochemistry standardisation, particularly PD-L1 and HER2 scoring. He coordinates the Asia-Pacific IHC Harmonisation Network and has supervised ring studies involving over 200 laboratories across the region.
Associate Editor, AI & Innovation
Computational Pathology & Machine Learning
University of Lagos Teaching Hospital, Nigeria
Dr. Okonkwo has led groundbreaking multi-centre AI validation studies and champions the development of training datasets that represent diverse populations. She co-chairs the African Computational Pathology Initiative and advises the Nigerian Health Ministry on AI regulation in diagnostics.
Section Editor, Renal Pathology
Nephropathology & Transplant Pathology
Centre Hospitalier Universitaire Ibn Sina, Casablanca
Professor Benhaddou chairs the Global Renal Pathology Consortium and led the development of international consensus recommendations for standardised renal biopsy reporting. Her research focuses on IgA nephropathy prognostication and the application of machine learning to glomerular lesion quantification.
Section Editor, Molecular Diagnostics
Liquid Biopsy & Circulating Biomarkers
Institut Jules Bordet, Brussels
Dr. Moreau is a leading authority on circulating tumour DNA analysis and its application in minimal residual disease detection. Her prospective studies on ctDNA-guided adjuvant therapy in colorectal cancer have influenced international treatment guidelines. She serves on the ESMO Translational Research Working Group.
Section Editor, Uropathology
Genitourinary Pathology & AI Validation
National and Kapodistrian University of Athens, Greece
Dr. Papadimitriou specialises in prostate cancer grading and the validation of AI-based diagnostic tools in uropathology. She led the landmark international validation study of AI for Gleason grading and coordinates the European Uropathology AI Consortium, a network of 30 centres working to establish standardised benchmarks.
Section Editor, Hematopathology
Lymphoma Diagnostics & Flow Cytometry
Cleveland Clinic Abu Dhabi, UAE
Dr. Al-Shamsi is an authority on T-cell lymphoma diagnostics and the application of multiparametric flow cytometry in haematological malignancy classification. He leads the Middle East Hematopathology Network and has contributed to the ICC classification updates for mature T-cell neoplasms. His multi-institutional case series on rare lymphoma subtypes are frequently cited.
Browse complete tables of contents from recent issues of the Global Pathology Review. Each issue features original research, reviews, case reports, and expert commentary.
Theme: Foundation Models in Pathology
Editorial: The Transformer Revolution in Diagnostic Pathology — Prof. R. Krishnamurthy
Cover Story: Deep Learning-Based Detection of Invasive Breast Carcinoma in Whole Slide Images: A Multi-Centre Prospective Validation Study — Dr. A. Okonkwo, Dr. L. Hoffmann et al.
Original Research: Attention-Based Multiple Instance Learning for Gastric Cancer Subtyping: A Comparative Study — Dr. K. Watanabe, Prof. W.-L. Chen et al.
Original Research: Self-Supervised Pre-Training on Unlabelled Histopathology Images Improves Downstream Classification Accuracy — Dr. E. Okafor, Dr. J. Kowalski et al.
Review: Regulatory Pathways for AI-Based In Vitro Diagnostics Under the European IVDR — Dr. M. Rossi, Dr. A. Bergqvist
Technical Note: Benchmarking Inference Speed of Pathology Foundation Models on Clinical-Grade Hardware — Dr. S. Jensen, Dr. O. Al-Balushi
Correspondence: Bias in AI Training Data: Lessons from Dermatopathology — Dr. L. Fernandez-Garcia, Prof. A. Adeola
Book Review: Computational Pathology: Principles and Practice (2nd Edition) — Dr. V. Petrov
Theme: Digital Laboratory Transformation
Editorial: From Glass to Glass-Free: The Economics of Digital Transformation — Prof. C. Dubois
Original Research: Clinical Validation of Whole Slide Imaging for Primary Histopathological Diagnosis: A Prospective Multisite Study Across Five European Centres — Dr. S. Papadimitriou, Prof. J.-M. Lefebvre et al.
Original Research: Cost-Effectiveness Analysis of Digital Pathology Implementation in a Tertiary Hospital Network — Dr. A. Mohammed, Dr. K. Al-Shamsi et al.
Case Study: Complete Digital Transformation of a 500-Bed Hospital Pathology Service: A Three-Year Retrospective — Dr. H. Yamamoto, Dr. T. Nakamura
Review: Interoperability Standards for Digital Pathology: DICOM, IHE, and HL7 FHIR — Dr. S. Jensen, Dr. J. Kowalski
Guidelines: International Consensus Recommendations for Standardisation of Renal Biopsy Reporting — Prof. N. Benhaddou, Dr. J. Park et al.
Short Communication: Telepathology for Intraoperative Consultation: A Five-Year Experience from a Remote Hospital Network — Dr. E. Asiedu, Dr. B. Osei-Mensah
Correspondence: Data Security Considerations for Cloud-Based Whole Slide Image Storage — Dr. M. Konstantinova, Dr. A. Lindqvist
Theme: Molecular Diagnostics Innovation
Editorial: The Liquid Biopsy Paradigm Shift — Dr. I. Moreau
Original Research: Novel Molecular Markers for Risk Stratification in Lung Adenocarcinoma: An Integrated Multi-Omics Approach — Prof. W.-L. Chen, Dr. F. Al-Dosari et al.
Original Research: Circulating Tumour DNA for Minimal Residual Disease Detection in Stage II-III Colorectal Cancer — Dr. I. Moreau, Dr. K. Asante et al.
Original Research: Next-Generation Sequencing on Cytology Specimens: Feasibility and Diagnostic Yield in Thyroid Fine-Needle Aspirates — Dr. Y. Haddad, Dr. K. Watanabe et al.
Review: Pan-Cancer Homologous Recombination Deficiency Testing: Assay Platforms, Clinical Utility, and Implementation Challenges — Dr. K. Nowak, Prof. D. Nikolaou
Technical Report: Optimising Computational Pathology Workflows: Infrastructure, Data Governance, and Integration with Laboratory Information Systems — Prof. R. Krishnamurthy, Dr. S. Jensen et al.
Case Report: Rare NTRK Fusion in Secretory Carcinoma of the Salivary Gland Identified by Comprehensive Genomic Profiling — Dr. C. Mendoza-Reyes, Dr. P. Nair
Correspondence: Companion Diagnostic Development for Novel Targeted Therapies: Regulatory Perspectives — Dr. M. Johansson, Dr. A. Petrovic
Theme: Haematological Malignancies
Editorial: Evolving Classification Systems in Haematopathology — Dr. K. Al-Shamsi
Original Research: Primary Cutaneous Gamma-Delta T-Cell Lymphoma: A Multi-Institutional Case Series of 34 Patients — Dr. K. Al-Shamsi, Dr. Y. Tanaka et al.
Original Research: Measurable Residual Disease Assessment by Multiparametric Flow Cytometry in Acute Myeloid Leukaemia: Optimisation of the EuroFlow Panel — Dr. E. Volkov, Dr. B. Osei-Mensah et al.
Review: EBV-Positive Diffuse Large B-Cell Lymphoma: Clinicopathological Spectrum and Diagnostic Pitfalls — Dr. Y. Tanaka, Dr. A. Lindqvist
Case Report: Grey Zone Lymphoma with Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma: Diagnostic Approach and Literature Review — Dr. S. Deshmukh, Prof. E. Volkov
Guidelines: Updated Recommendations for Bone Marrow Biopsy Reporting in Myeloproliferative Neoplasms — Dr. M. Johansson, Dr. J. Park et al.
Short Communication: Droplet Digital PCR for BCR-ABL1 Monitoring in CML: Comparison with Real-Time Quantitative PCR — Dr. M. Konstantinova, Dr. K. Nowak
Book Review: Atlas of Bone Marrow Pathology (3rd Edition) — Dr. E. Asiedu
Theme: Immunohistochemistry & Predictive Biomarkers
Editorial: Beyond PD-L1: The Next Generation of Predictive Biomarkers — Dr. H. Yamamoto
Original Research: PD-L1 Scoring Harmonisation Across Four Commercial Assays: A 6,000-Case Multi-Laboratory Ring Study — Dr. H. Yamamoto, Prof. C. Dubois et al.
Original Research: Automated Ki-67 Quantification Using Deep Learning: Correlation with Manual Assessment Across 2,400 Cases — Dr. S. Patel, Prof. R. Gupta et al.
Review: HER2 Low Expression in Breast Cancer: Diagnostic Challenges and Therapeutic Implications — Dr. L. Hoffmann, Dr. I. Svensson
Systematic Review: Artificial Intelligence in Melanocytic Lesion Assessment: A Systematic Review and Meta-Analysis — Dr. L. Fernandez-Garcia, Prof. A. Adeola et al.
Technical Report: External Quality Assessment for Immunohistochemistry: 10-Year Trends from the Nordic IHC Programme — Dr. A. Bergqvist, Dr. A. Lindqvist
Case Report: Unusual Presentation of IgG4-Related Disease in Renal Biopsy with Concurrent Membranous Nephropathy — Dr. F. Al-Najjar, Prof. N. Benhaddou
Correspondence: PRAME Immunohistochemistry: A Practical Review for the Diagnostic Dermatopathologist — Dr. H. Müller-Weber, Dr. S. Deshmukh
Theme: Pathology Workforce & Education
Editorial: Addressing the Global Pathology Workforce Shortage — Prof. R. Krishnamurthy, Prof. C. Dubois
Original Research: Global Survey of Pathology Training Programmes: Duration, Curriculum, and Sub-Specialisation Pathways — Dr. E. Asiedu, Dr. Y. Haddad et al.
Original Research: Impact of Digital Pathology on Trainee Education: A Prospective Multicentre Controlled Study — Dr. M. Rossi, Dr. J. Ferreira et al.
Review: Continuing Professional Development in Pathology: International Models and Best Practices — Dr. A. Mohammed, Dr. S. Sharma
Perspective: Pathology in Sub-Saharan Africa: Challenges, Innovations, and the Role of Technology — Dr. A. Okonkwo, Dr. B. Osei-Mensah, Dr. K. Asante
Technical Report: Virtual Microscopy for Assessment: Validity, Reliability, and Candidate Acceptance — Dr. A. Bergqvist, Dr. M. Johansson
Short Communication: Simulation-Based Training for Intraoperative Frozen Section Consultation — Dr. T. Nakamura, Dr. K. Watanabe
Correspondence: Mentorship Programmes for Early-Career Pathologists: Outcomes from the GPP Mentorship Initiative — Dr. C. Mendoza-Reyes, Dr. P. Nair
Essential information for preparing and submitting manuscripts to the Global Pathology Review. Complete author guidelines are available on the Publish With Us page.
Original Research: Up to 5,000 words excluding references, tables, and figure legends. Structured abstract of 350 words maximum (Background, Methods, Results, Conclusions). Maximum 50 references, 8 figures/tables combined.
Review Articles: Up to 7,000 words. Structured or narrative abstract of 400 words. Maximum 100 references, 10 figures/tables. Systematic reviews must follow PRISMA guidelines.
Case Reports: Up to 2,500 words. Unstructured abstract of 200 words. Maximum 20 references, 6 figures. Must include clinical significance statement and patient consent documentation.
Short Communications: Up to 1,500 words. Unstructured abstract of 150 words. Maximum 15 references, 3 figures/tables.
Technical Reports: Up to 4,000 words. Structured abstract. Maximum 40 references, 6 figures/tables. Must include a reproducibility statement detailing protocols, reagents, and analysis code availability.
Editorials & Correspondence: Up to 1,000 words. No abstract. Maximum 10 references.
Reference Style: Vancouver (numbered) style. References numbered consecutively in the order of first citation in the text. Use PubMed-formatted abbreviations for journal names. Include DOI where available. All references must be cited in the text; uncited references will be removed during copy-editing.
Figure Requirements: Minimum 300 DPI for photographs and photomicrographs. Vector format (SVG, EPS) preferred for diagrams and charts. Maximum file size 10 MB per figure. All histopathology images must include magnification and stain information in the legend. Scale bars are required for photomicrographs. Colour figures published at no additional cost.
Data Availability: Authors must include a data availability statement. Raw data should be deposited in an appropriate public repository (e.g., GEO for genomic data, TCGA for cancer datasets, Zenodo for general research data). Analysis code should be made available via GitHub or equivalent platform with a permanent DOI via Zenodo.
Supplementary Materials: Supplementary tables, figures, videos, and datasets are accepted and published online alongside the main article. No word limit for supplementary text.
Review Model: Double-blind peer review. At least two independent reviewers are assigned to each manuscript by the handling editor. Reviewers are selected for subject-matter expertise and absence of conflicts of interest. Authors may suggest up to three preferred and three non-preferred reviewers; the editorial team retains full discretion.
Timeline: Editorial triage decision within 5 working days of submission. First peer review decision within 28 days (median 14 days). Revised manuscripts reviewed within 14 days. Acceptance to online publication within 10 working days. Final typeset and DOI-assigned version within 21 days of acceptance.
Revision Policy: Major revisions must be resubmitted within 60 days; minor revisions within 30 days. Extensions may be granted on request. A point-by-point response to reviewers is required with all revisions. Changes in the manuscript must be highlighted using tracked changes or coloured text.
Appeals: Authors may appeal editorial decisions by submitting a detailed rebuttal letter within 30 days of the decision. Appeals are reviewed by a member of the Editorial Board not involved in the original decision.
Reporting Standards: Authors must follow the appropriate EQUATOR Network reporting guideline for their study type: CONSORT for randomised trials, STROBE for observational studies, PRISMA for systematic reviews, STARD for diagnostic accuracy studies, CARE for case reports, TRIPOD for prediction models, and CLAIM for AI/machine learning studies in medical imaging. A completed checklist must be submitted with the manuscript.
Ethics Approval: Studies involving human participants must have ethics committee / institutional review board approval. The approval number and name of the approving body must be stated in the Methods section. Studies using only anonymised archived tissue may be eligible for a waiver of informed consent, but this must be explicitly stated with the relevant ethics committee reference.
Conflicts of Interest: All authors must disclose financial and non-financial conflicts of interest using the ICMJE disclosure form, submitted at the time of manuscript submission. Disclosures are published alongside the article.
Author Contributions: Author contributions must be described using the CRediT (Contributor Roles Taxonomy) framework. All individuals listed as authors must meet the ICMJE criteria for authorship. The use of AI-assisted tools in manuscript preparation must be disclosed in the Methods section.
The Global Pathology Review welcomes original research, review articles, case reports, and technical reports from pathologists, researchers, and allied health scientists worldwide. Our rigorous double-blind peer review process, rapid publication timeline, and gold open access policy ensure your work reaches the widest possible audience. No article processing charges for authors from low- and middle-income countries.